Aberdeen Group plc bought a new position in shares of Medline (NASDAQ:MDLN – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 36,597 shares of the company’s stock, valued at approximately $1,270,000.
Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its position in Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after acquiring an additional 254 shares in the last quarter. Reyes Financial Architecture Inc. acquired a new position in shares of Medline during the 3rd quarter worth $30,000. NewEdge Advisors LLC increased its holdings in shares of Medline by 100.0% in the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 475 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Medline by 86.2% in the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after purchasing an additional 487 shares in the last quarter. Finally, Assetmark Inc. purchased a new position in shares of Medline in the 1st quarter valued at about $62,000.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada reduced their price target on shares of Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Citigroup upped their price target on Medline from $45.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. William Blair restated an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. Mizuho dropped their price objective on Medline from $48.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. Finally, Robert W. Baird set a $42.00 price objective on Medline in a report on Thursday, August 6th. Twenty-three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.15.
Insider Buying and Selling
In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the transaction, the insider owned 16,453,806 shares of the company’s stock, valued at approximately $576,705,900.30. The trade was a 11.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 6,348,676 shares of company stock worth $224,525,137. Company insiders own 0.81% of the company’s stock.
Medline Stock Performance
Medline stock opened at $37.02 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.04. The stock has a fifty day moving average of $35.69 and a two-hundred day moving average of $39.21. The company has a market capitalization of $48.69 billion and a price-to-earnings ratio of 84.14. Medline has a fifty-two week low of $31.37 and a fifty-two week high of $50.88.
Medline (NASDAQ:MDLN – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The company had revenue of $7.86 billion during the quarter. On average, analysts anticipate that Medline will post 1.58 EPS for the current fiscal year.
Key Medline News
These are some of the MDLN news items that stood out recently:
- Positive Sentiment: Zacks Research upgraded Medline from “strong sell” to “hold,” a less bearish assessment. Zacks Research rating information
- Neutral Sentiment: Medline saw unusually large options volume, which may signal heightened trading interest but does not establish whether investors are bullish or bearish. Report on Medline options volume
- Negative Sentiment: Medline announced pricing for a secondary share offering, which could create near-term supply or overhang concerns for the stock. Medline secondary offering announcement
Medline Company Profile
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Further Reading
- Five stocks we like better than Medline
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN – Free Report).
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
